Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: French multicentre survey on the use of inotropes after cardiac surgery. | Available online http content 9 3 241 Commentary French multicentre survey on the use of inotropes after cardiac surgery Olivier Bastien1 and Benoit Vallet2 on behalf of the French Study Group AGIR AGents Inotropes en chiRurgie cardiaque Service d anesthésie-réanimation et équipe d accueil 1896 Hôpital Cardiovasculaire et Pneumologique Louis-Pradel Lyon-Montchat Lyon France 2Departement d anesthesie-reanimation Hôpital Claude-Huriez Lille France Corresponding author Olivier Bastien Published online 23 February 2005 This article is online at http content 9 3 241 2005 BioMed Central Ltd Critical Care 2005 9 241-242 DOI cc3482 See review page 266 http content 9 3 266 Abstract Results from a French multicentre survey on the use of inotropes after cardiac surgery are presented. Consideration of these findings which strictly apply only to France highlights the importance of developing monitoring strategies to help in decision making regarding therapy with inotropes in this context. During the postoperative period after weaning from cardiopulmonary bypass CPB patients are at increased risk for developing a low cardiac output syndrome LCOS . Despite the availability of a wide range of inotropic agents no consensus exists regarding the treatment of LCOS after CPB. In this issue of Critical Care Gillies and coworkers 1 review the literature systematically in order to identify present and classify the evidence regarding choice of inotropic drugs. They observe that insufficient data exist to allow selection of a specific inotropic agent in preference over another in adult cardiac surgery patients that inodilators such as dobutamine and phosphodiesterase inhibitors are efficacious in the management of LCOS that although all p-agonists can increase cardiac output the best studied p-agonist and the one with the most favourable side effect profile appears to be dobutamine and that phosphodiesterase inhibitors
